AI-adopting incumbents · Industry Index 13 (rank #71) ·
price: as of 2026-10-29 index: as of 2026-10-29 fundamentals: latest filing 2026-08-04 Reports quarterly (10-Q XBRL)
Global biopharma; co-developed the BNT162b2 COVID-19 vaccine with BioNTech and runs a broad small-molecule and biologics pipeline.
Industry exposure 0.1 (AI-adopting incumbent, not an AI vendor. Its FY2025 10-K names "Scale AI across our business" as one of four 2026 priorities and cites "automation and AI" as a driver of its cost programs, but names no AI counterparty; the graph edge comes from Tempus AI's own release describing Pfizer's access to its AI-enabled platform.)
Delayed, end-of-day, aggregate per contract — not a live tape or trade-level flow. Buy/sell side is INFERRED from where each contract's last print sat in the bid/ask spread, not observed order flow. The company-wide side is withheld unless quoted contracts cover at least a quarter of the day's premium, so it can be blank while individual contracts below show a side. Call/put premium is measured across the chain we capture — the 6 nearest expiries within 45 days, not the full option chain — while the table below lists at most 20 flagged contracts, so summing those rows will not reproduce the percentage.
Why flagged:earnings in 6 days
20 small flags (under $100000 premium) — none large enough to highlight.
latest session: 0.5× its 13-day baseline
52% calls / 48% puts (by premium)
News set the tone, but the swarm won’t commit — a negative tilt with weak agreement, so the call is Neutral.
Most voters leaned one way; news dissented. Directional agreement 0.35.
A mildly-negative score, but weak agreement — so the engine returns a no-conviction Neutral rather than overclaim. This is the system refusing to force a call it doesn’t have.
Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book.
Rating: eroding
The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed.
Type: intangibles ip
The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section.
Leadership: co leader
The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.'
Pricing power: weak
Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price.
Curated moat judgment grounded in the cited source. source: sec.gov
Layer: AI-adopting incumbents
Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells.
Derived from this company's mapped supply-chain edges and its industry layer.
The moat prior voted -0.17 on the long (~6-month) horizon at weight 0.20 — the swarm call there is bearish (score -0.41, conviction 58).
Editorial prior — subjective, not backtested. It is bounded (±0.6), low-confidence, and never votes on short/medium. See exactly how it voted →
Products & services with an editorial market-share band and technical barrier band — qualitative judgments tied to a cited basis, never invented figures.
| Product | Market share | Technical barrier |
|---|---|---|
| Comirnaty · Primary Care - COVID-19 vaccine Active immunization to prevent COVID-19, commercialized in collaboration with BioNTech. | Unknown The filing gives direction but no level: 2025 declines were 'partially offset by lower returns and higher market share in the U.S.' Worldwide revenue was $4,367 million in 2025 against $5,353 million in 2024 and $11,220 million in 2023 - down 20% operationally in 2025, driven by lower contractual deliveries, lower international vaccination rates and 'lower utilization in the U.S. resulting from narrower recommendation for vaccination.' | Deep The longest patent runway Pfizer discloses - U.S. and Japan basic product patents to 2041, with the European application filed and, if granted, expected to run a full term. The instructive point is that this is the one franchise where the moat is not the binding constraint: revenue is falling on public-health recommendations and demand, not on generic entry, and the filing notes the economics run through a '50% gross profit split with BioNTech'. |
| Eliquis · Primary Care - anticoagulant Indicated for nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism; jointly developed and commercialized in collaboration with Bristol Myers Squibb. | Unknown The 10-K discloses no market share for Eliquis. What it does disclose is position within Pfizer: worldwide revenue of $7,961 million in 2025 against $7,366 million in 2024, up 7% operationally, and that Eliquis 'accounted for 13% of Total revenues in 2025' - the largest single line in the book. | Low The patent table gives a U.S. basic product patent year of 2027, but the footnote is more specific and less comfortable: the composition of matter patent expires in November 2026, Pfizer and BMS 'previously settled certain patent litigations with a number of generic companies permitting their launch of a generic version of Eliquis on April 1, 2028', three remaining litigants are blocked only to the 2031 formulation patent, and if that formulation patent is later held invalid the settled generics 'would be permitted to launch on November 21, 2026'. In Europe 'the apixaban basic product patent and associated SPC were invalidated in the U.K.' |
| Ibrance · Oncology - metastatic breast cancer Indicated for HR-positive/HER2-negative metastatic breast cancer. | Unknown No share level is given. Worldwide revenue fell to $4,122 million in 2025 from $4,367 million in 2024 and $4,753 million in 2023; the 10-K attributes the decline to lower U.S. net price from the IRA Medicare Part D Redesign and to 'generic entry in certain international markets', partially offset by 'improved market share supported by new clinical data' in the U.S. | Low Basic product patents expire in 2027 in the U.S. and 2028 in both major Europe and Japan, and the filing already reports generic entry in certain international markets ahead of those dates. |
| Padcev · Oncology - urothelial cancer Indicated for locally advanced or metastatic urothelial cancer and cisplatin-ineligible/decline muscle invasive bladder cancer; commercialized in collaboration with Astellas. | Unknown The 10-K reports direction, not level: 2025 growth of 22% to $1,940 million from $1,588 million was 'primarily driven by increased market share in first line locally advanced or metastatic urothelial cancer (la/mUC)', plus a one-time benefit from moving to a wholesaler distribution model in the U.S. The line carried $53 million of revenue in 2023, the year the filing says Pfizer 'completed the acquisition of Seagen' on December 14. | Moderate A U.S. basic product patent to 2033 gives this line the runway the older franchises have lost, but the economics are shared - Padcev 'is being commercialized in collaboration with Astellas', with Pfizer holding U.S. co-promotion rights and commercialization rights only in the Americas outside the U.S. - and the filing itself describes oncology, the area its Seagen deal invested into, as one of the 'extremely competitive therapeutic areas'. |
| Prevnar family · Primary Care - pneumococcal conjugate vaccine Prevnar 13/Prevenar 13 and Prevnar 20/Prevenar 20, for active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae. | Unknown No share figure appears in the filing. Family revenue was $6,494 million in 2025 against $6,411 million in 2024, up 1% operationally, with U.S. revenue down 2%; the 10-K attributes the flat result partly to 'lower shipments and competitive pressure in certain international markets' offset by uptake of the adult indication following the CDC's recommendation for ages 50-64. | Moderate The generational split is doing the work. The 10-K dates the Prevnar 13/Prevenar 13 U.S. basic product patent to 2026, and notes that in Europe the patent covering the combination of the 13 serotype conjugates 'was revoked following an opposition and has now been withdrawn' - though other European formulation and manufacturing-process patents 'remain in force'. Prevnar 20/Prevenar 20 runs to 2035 in the U.S., 2037 in major Europe and 2038 in Japan, so the franchise's protection survives the older product's expiry only to the extent demand migrates. |
| Vyndaqel family · Specialty Care - transthyretin amyloidosis Vyndaqel, Vyndamax and Vynmac (tafamidis), indicated for ATTR-CM and polyneuropathy. | Unknown The 10-K states no share. Worldwide revenue was $6,380 million in 2025 against $5,451 million in 2024, up 16% operationally, growth the filing attributes to 'strong demand with continuing uptake in patient diagnosis' and improved U.S. patient affordability, partially offset by lower U.S. net price - a diagnosis-expansion story rather than a share-capture one. | Low The nearest-dated protection on a top-three franchise. The U.S. basic product patent year is given as 2026, and the footnote states that 'interim patent term extension requests have been granted extending the expiry from December 2025 to December 2026, and Pfizer has pending applications for patent term extension to 2028' - the 2028 date is an application, not a grant. Major Europe is 2026, and in Japan the Vyndaqel basic patent expires August 2026 for polyneuropathy, with Vynmac protected only by regulatory exclusivity to March 2029. |
These charts plot Pfizer's reported income statement, cash flow, and balance sheet from its SEC filings through 2026-08-04. Every figure is as-filed XBRL — none of it is an estimate.
Over the reported window, net income at $7.8B in FY2025.
Analyst consensus — third-party estimates from Yahoo Finance, as of 2026-10-26. Not SEC filings and not a TradingPilot forecast. source: finance.yahoo.com
| Period | EPS (est.) | Revenue (est.) | YoY |
|---|---|---|---|
| Q/E Sep 2026 | USD 0.73 (USD 0.56–USD 0.83) · 19 | USD 15.9B (USD 14.7B–USD 16.2B) · 17 | -5% |
| FY 2026 | USD 2.96 (USD 2.88–USD 3.07) · 24 | USD 62.2B (USD 61.2B–USD 63.3B) · 25 | -1% |
Each figure shows the consensus mean, its (low–high) range where available, and · the number of analysts behind that estimate.
Next report ~2026-11-03.
Our model leans Low-confidence · Neutral on the stock over the medium horizon — a market-direction call, not an earnings forecast. See the Signal tab.
Comparing against peers…
| Institution | Shares | Value | Δ shares QoQ | % of 13F | % shares out |
|---|---|---|---|---|---|
| BlackRock Passive / index | 529,670,433 | $12.8B | 31,412,883 | 0.2% | 9.29% |
| State Street Passive / index | 307,090,897 | $7.4B | 5,501,032 | 0.2% | 5.39% |
| FMR (Fidelity) Passive / index | 15,397,294 | $370.8M | 2,829,936 | 0.0% | 0.27% |
| Bridgewater Associates (Ray Dalio (founder)) Guru | 180,092 | $4.3M | 180,092 | 0.0% | 0.00% |
TradingPilot-computed columns (% of 13F, % shares out) are derived from as-filed 13F values; only name, shares and value are as-filed.
| Position | Shares | Value | Reported price | % of book | Activity |
|---|---|---|---|---|---|
| ALLOGENE THERAPEUTICS INC | 22,032,040 | $46.9M | $2.13 | 27.5% | Held |
| CELCUITY INC | 295,652 | $29.6M | $99.95 | 17.3% | Held |
| ARVINAS INC | 3,457,815 | $27.7M | $8.00 | 16.2% | Held |
| PYXIS ONCOLOGY INC | 7,032,770 | $19.5M | $2.77 | 11.4% | Held |
| WAVE LIFE SCIENCES LTD | 1,875,000 | $10.9M | $5.83 | 6.4% | Held |
| BIOHAVEN LTD | 505,645 | $8.0M | $15.83 | 4.7% | Held |
| CARIBOU BIOSCIENCES INC | 4,690,431 | $7.9M | $1.68 | 4.6% | Held |
| SPERO THERAPEUTICS INC | 2,362,348 | $5.3M | $2.26 | 3.1% | Held |
| ZENTALIS PHARMACEUTICALS INC | 953,834 | $3.9M | $4.04 | 2.3% | Held |
| ORIC PHARMACEUTICALS INC | 372,904 | $3.6M | $9.53 | 2.1% | Trimmed |
| CARDIFF ONCOLOGY INC | 2,411,575 | $3.0M | $1.25 | 1.8% | Held |
| ZURA BIO LTD | 538,841 | $2.9M | $5.35 | 1.7% | Trimmed |
| AGOMAB THERAPEUTICS NV | 75,000 | $1.0M | $13.81 | 0.6% | Held |
| BOLT BIOTHERAPEUTICS INC | 31,305 | $133832 | $4.28 | 0.1% | Held |
| NEXTCURE INC | 44,347 | $72967 | $1.65 | 0.0% | Trimmed |
| GINKGO BIOWORKS HOLDINGS INC | 2,928 | $30012 | $10.25 | 0.0% | New |
| SENSEONICS HLDGS INC | 2,171 | $12418 | $5.72 | 0.0% | Held |
| Q32 BIO INC | 0 | $0 | — | — | Sold-Out |
Showing all 17 reported 13(f) positions; 0 link to the TradingPilot universe. Reported price is value ÷ shares at the quarter-end — an average, not a buy/sell price.
Yahoo Finance (Business Wire) · 2026-10-27 · product
Pfizer said MagnetisMM-32 met its primary progression-free-survival endpoint against investigator-selected regimens in relapsed or refractory multiple myeloma. Overall-survival data remain immature, and the company plans regulatory submissions; these results are not a new approval.
Yahoo Finance (Business Wire) · 2026-10-26 · regulation
Pfizer announced FDA approval of TALZENNA with XTANDI for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, expanding the combination’s use into an earlier treatment setting.
FDA · 2026-10-26 · regulation
The FDA approved talazoparib with enzalutamide for adults with metastatic androgen pathway modulation-naive or sensitive prostate cancer with HRR gene mutations, as detected by an FDA-authorized test.
Pfizer · 2026-10-14 · product
Pfizer will present infectious-disease research at IDWeek on October 21–24, including pediatric pneumococcal vaccine data, Phase 3 Lyme vaccine results and real-world RSV vaccine evidence. The announcement previews conference presentations and does not announce a new regulatory approval.
Enodia Therapeutics · 2026-10-13 · partnership
Enodia Therapeutics entered a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitor small molecules against multiple collaboration targets; after the collaboration term Pfizer will be responsible for all clinical, manufacturing, regulatory and commercial activities. Enodia will receive an upfront payment and is eligible for milestone payments and tiered royalties, bringing the total potential value to more than $500 million.
Pfizer · 2026-10-07 · product
Pfizer said the FDA approved Tukysa (tucatinib) with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable locally advanced or metastatic HER2+ breast cancer following induction treatment, expanding its use to the front-line setting. In the Phase 3 HER2CLIMB-05 trial, median investigator-assessed progression-free survival was 24.9 months versus 16.3 months in the placebo arm (hazard ratio 0.64).
GlobeNewswire · 2026-09-29 · partnership
Nurix announced a $7 million research milestone under its existing Pfizer collaboration to develop degrader antibody conjugates. The company said the achievement advances research under the agreement originally signed with Seagen.
Viet Nam News · 2026-09-23 · partnership
During a visit by Vietnam's General Secretary and President Tô Lâm to Pfizer in New York on September 22, a cooperation document between Pfizer and Vietnam Vaccine Joint Stock Company (VNVC) on strengthening vaccine immunisation and disease-prevention capacity in Vietnam was handed over. The article notes that VNVC previously signed a cooperation agreement with Pfizer in March 2025 to share knowledge and build capacity in producing high-quality vaccines.
Yahoo Finance · 2026-09-19 · regulation
Pfizer's 'most favored nation' contract with the Trump administration, released by Public Citizen after a FOIA lawsuit, shows Pfizer agreed to share a portion of its net increased revenue from charging higher prices abroad with HHS. The provision covers medicines already on the market and runs from Jan. 1, 2026, through Jan. 20, 2029; the sharing rate and the medicines covered are redacted.
JUVE Patent · 2026-09-18 · regulation
The EPO Boards of Appeal revoked Moderna's European patent EP 3 590 949, the key mRNA vaccine patent on which Moderna had brought legal action against BioNTech and Pfizer. The decision nullifies Moderna's earlier wins before national courts in London and Düsseldorf, though litigation between the parties is likely to continue.
GlobeNewswire · 2026-08-27 · regulation
Pfizer and BioNTech announced U.S. FDA approval of their COVID-19 vaccine adapted to the XFG variant, the strain update for the 2026-2027 season.
GlobeNewswire · 2026-08-14 · regulation
The European Medicines Agency validated the Marketing Authorization Application for PF-07307405, the Lyme disease vaccine candidate developed by Pfizer with partner Valneva, and will begin its assessment. The application is based on Phase 3 VALOR trial efficacy of more than 70%, with no safety concerns identified.
Yahoo Finance · 2026-08-13 · personnel
Pfizer's chairman and CEO purchased roughly $1 million of Pfizer shares, an insider buy disclosed in an SEC filing following the company's Q2 report and raised 2026 guidance.
Yahoo Finance · 2026-08-12 · regulation
Pfizer agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims about product safety disclosures.
Pfizer · 2026-07-30 · product
Pfizer reported positive topline results from the Phase 3 TRANQUILLO and TRANQUILLO 2 studies of LITFULO (ritlecitinib) in nonsegmental vitiligo. Per the release, "Across both studies, significantly more patients treated with LITFULO achieved F-VASI75 (>=75% improvement in Facial Vitiligo Area Scoring Index) and T-VASI50 (>=50% improvement in Total Vitiligo Area Scoring Index) from baseline at Week 52 compared with placebo." Pfizer states it "intends to submit global regulatory filings for LITFULO as a potential new oral systemic therapy for NSV for adults."
PMLiVE · 2026-07-22 · regulation
The FDA granted priority review to Pfizer's combination of Talzenna and Xtandi in men with metastatic castration-sensitive prostate cancer whose tumours carry HRR mutations. Priority review shortens the FDA review period to six months from the standard 10 months. The application is supported by the Phase 3 TALAPRO-3 trial, in which the combination reduced the risk of radiographic progression or death by 52% versus placebo plus Xtandi.
Google News: Pfizer · 2026-07-15 · product
Pfizer's Lyme disease vaccine showed 70% efficacy in trial results.
Google News: Pfizer · 2026-07-15 · regulation
Pfizer announced FDA approval of PADCEV plus Keytruda for muscle-invasive bladder cancer.
2026-10-29 Business Wire AI · Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
2026-10-28 Yahoo Finance: PFE · Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
2026-10-28 Yahoo Finance: PFE · Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?
2026-10-28 Yahoo Finance: PFE · Why Should Pfizer Stock Holders Watch This One Number?
2026-10-27 Yahoo Finance: PFE · Pfizer (PFE) Scores Phase 3 Cancer Win As FDA Broadens Another Oncology Approval
2026-10-27 Yahoo Finance: PFE · Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-27 Business Wire Health · Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
2026-10-27 Yahoo Finance: PFE · Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
2026-10-26 Yahoo Finance: PFE · Pfizer Rose Nearly 21% in 2026 as Its Forward P/E Climbed From About 9 to 11 Times. Here’s What November 3 Has to Show
2026-10-26 Yahoo Finance: PFE · Pfizer (PFE) Stock Looks Above Fair Value As 30% Run Continues
2026-10-26 Business Wire Health · Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
2026-10-26 Yahoo Finance: PFE · Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
2026-10-24 Business Wire Health · Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
2026-10-19 Yahoo Finance: PFE · Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch
2026-10-17 Yahoo Finance: PFE · Pfizer or Kraft Heinz: Only One Gets My Dividend Dollars for the Next 10 Years
2026-10-16 Yahoo Finance: PFE · Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
2026-10-16 Yahoo Finance: PFE · Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?
2026-10-16 Yahoo Finance: PFE · What to Expect From Pfizer's Q3 2026 Earnings Report
2026-10-14 Business Wire Health · Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
2026-10-13 Business Wire Health · Resumen: Enodia Therapeutics anuncia un acuerdo de colaboración en investigación y licencia con Pfizer para desarrollar moléculas pequeñas dirigidas contra el Sec61
Impact = company-prominence tier (High/Medium auto-assigned by graph centrality/size; Low only on curated minor events), not a magnitude forecast.
| Date | Type | Event | Impact |
|---|---|---|---|
| 2026-11-03 | earnings | Pfizer earnings (estimated) — Date not yet announced — estimated from EDGAR filing cadence (last periodic filing + 91/365 days); confirm via IR. estimated | Medium |
| Date | Event | Impact | Outcome |
|---|---|---|---|
| 2026-08-04 | Pfizer earnings confirmed | High | EPS beat · +1.6% |
| 2026-05-05 | Pfizer earnings confirmed | High | EPS beat · +0.3% |
